Roivant Sciences combination with Montes Archimedes Acquisition
We are advising Roivant Sciences on its combination with a SPAC
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
EDAP TMS $28 million follow-on offering
We advised the underwriters on the equity offering
Zai Lab $857.5 million offering of American depositary shares and ordinary shares
We advised Zai Lab on the concurrent offerings
NeuroPace $102 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Lannett Company $350 million senior secured notes offering
We advised the initial purchasers on the high-yield notes offering
Recursion Pharmaceuticals $500 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Diagnósticos da América R$3.3 billion equity offering
We advised the global coordinators and joint bookrunners on the Rule 144A / Regulation S offering
Ionis Pharmaceuticals $632.5 million convertible senior notes offering
We advised the purchasers on the Rule 144A convertible notes offering
Maravai LifeSciences $646.9 million secondary offering
We advised the joint book-running managers on the equity offering
Beam Therapeutics $300 million at-the-market offering
We advised the sales agent in connection with the equity offering